> top > docs > PubMed:22868358 > annotations

PubMed:22868358 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCoin-PubTator-for-Tuning

Id Subject Object Predicate Lexical cue tao:has_database_id
5 16-19 OrganismTaxon denotes HBV Tax:10407
6 36-45 OrganismTaxon denotes hepatitis Tax:10407
7 56-80 DiseaseOrPhenotypicFeature denotes hepatocellular carcinoma MESH:D006528
8 118-126 OrganismTaxon denotes patients Tax:9606
9 149-152 OrganismTaxon denotes HBV Tax:10407
51 221-238 OrganismTaxon denotes hepatitis B virus Tax:10407
52 240-243 OrganismTaxon denotes HBV Tax:10407
53 330-338 OrganismTaxon denotes patients Tax:9606
54 344-347 OrganismTaxon denotes HBV Tax:10407
55 356-380 DiseaseOrPhenotypicFeature denotes hepatocellular carcinoma MESH:D006528
56 413-416 OrganismTaxon denotes HBV Tax:10407
57 464-467 OrganismTaxon denotes HBV Tax:10407
58 536-545 OrganismTaxon denotes hepatitis Tax:10407
59 573-581 OrganismTaxon denotes patients Tax:9606
60 704-707 OrganismTaxon denotes HBV Tax:10407
61 781-789 OrganismTaxon denotes PATIENTS Tax:9606
62 815-823 OrganismTaxon denotes patients Tax:9606
63 898-901 OrganismTaxon denotes HBV Tax:10407
64 936-944 OrganismTaxon denotes patients Tax:9606
65 970-978 OrganismTaxon denotes patients Tax:9606
66 985-988 OrganismTaxon denotes HBV Tax:10407
67 1080-1109 GeneOrGeneProduct denotes hepatitis B e antigen (HBeAg) Gene:944568
68 1135-1138 OrganismTaxon denotes HBV Tax:10407
69 1203-1215 DiseaseOrPhenotypicFeature denotes inflammation MESH:D007249
70 1453-1456 OrganismTaxon denotes HBV Tax:10407
71 1471-1474 OrganismTaxon denotes HBV Tax:10407
72 1563-1576 DiseaseOrPhenotypicFeature denotes liver failure MESH:D017093
73 1585-1593 OrganismTaxon denotes patients Tax:9606
74 1599-1602 OrganismTaxon denotes HBV Tax:10407
75 1799-1807 OrganismTaxon denotes patients Tax:9606
76 1813-1816 OrganismTaxon denotes HBV Tax:10407
77 2003-2006 OrganismTaxon denotes HBV Tax:10407
78 2029-2041 DiseaseOrPhenotypicFeature denotes inflammation MESH:D007249
79 2145-2148 OrganismTaxon denotes HBV Tax:10407
80 2227-2230 OrganismTaxon denotes HBV Tax:10407
81 2263-2266 OrganismTaxon denotes HBV Tax:10407
82 2299-2304 DiseaseOrPhenotypicFeature denotes tumor MESH:D009369
83 2383-2402 DiseaseOrPhenotypicFeature denotes vein tumor thrombus MESH:D013927
84 2502-2505 OrganismTaxon denotes HBV Tax:10407
85 2547-2555 DiseaseOrPhenotypicFeature denotes fibrosis MESH:D005355
86 2581-2586 DiseaseOrPhenotypicFeature denotes tumor MESH:D009369
87 2673-2692 DiseaseOrPhenotypicFeature denotes vein tumor thrombus MESH:D013927
88 2770-2773 OrganismTaxon denotes HBV Tax:10407
89 2838-2841 OrganismTaxon denotes HBV Tax:10407
90 2896-2899 OrganismTaxon denotes HBV Tax:10407
91 2936-2939 OrganismTaxon denotes HBV Tax:10407

LitCoin-Disease-Tuning-1

Id Subject Object Predicate Lexical cue ID:
T1 36-47 DiseaseOrPhenotypicFeature denotes hepatitis B D006509
T2 56-80 DiseaseOrPhenotypicFeature denotes hepatocellular carcinoma D006528
T3 221-232 DiseaseOrPhenotypicFeature denotes hepatitis B D006509
T4 356-380 DiseaseOrPhenotypicFeature denotes hepatocellular carcinoma D006528
T5 382-385 DiseaseOrPhenotypicFeature denotes HCC DISEASE|D006528
T7 536-547 DiseaseOrPhenotypicFeature denotes hepatitis B D006509
T8 1038-1041 DiseaseOrPhenotypicFeature denotes HCC DISEASE|D006528
T10 1042-1052 DiseaseOrPhenotypicFeature denotes recurrence D012008
T11 1080-1091 DiseaseOrPhenotypicFeature denotes hepatitis B D006509
T12 1203-1215 DiseaseOrPhenotypicFeature denotes inflammation DISEASE|D007249
T14 1563-1576 DiseaseOrPhenotypicFeature denotes liver failure D017093
T15 1715-1722 DiseaseOrPhenotypicFeature denotes disease D004194
T16 2029-2041 DiseaseOrPhenotypicFeature denotes inflammation DISEASE|D007249
T18 2299-2304 DiseaseOrPhenotypicFeature denotes tumor D009369
T19 2388-2393 DiseaseOrPhenotypicFeature denotes tumor D009369
T20 2394-2402 DiseaseOrPhenotypicFeature denotes thrombus D013927
T21 2427-2443 DiseaseOrPhenotypicFeature denotes resection margin D000072662
T22 2547-2555 DiseaseOrPhenotypicFeature denotes fibrosis D005355
T23 2581-2586 DiseaseOrPhenotypicFeature denotes tumor D009369
T24 2678-2683 DiseaseOrPhenotypicFeature denotes tumor D009369
T25 2684-2692 DiseaseOrPhenotypicFeature denotes thrombus D013927
T26 2696-2712 DiseaseOrPhenotypicFeature denotes resection margin D000072662
T27 2908-2911 DiseaseOrPhenotypicFeature denotes HCC DISEASE|D006528

LitEisuke

Id Subject Object Predicate Lexical cue #label
T1 36-47 DiseaseOrPhenotypicFeature denotes hepatitis B D006509
T2 56-80 DiseaseOrPhenotypicFeature denotes hepatocellular carcinoma D006528
T3 221-232 DiseaseOrPhenotypicFeature denotes hepatitis B D006509
T4 356-380 DiseaseOrPhenotypicFeature denotes hepatocellular carcinoma D006528
T5 382-385 DiseaseOrPhenotypicFeature denotes HCC DISEASE|D006528
T7 536-547 DiseaseOrPhenotypicFeature denotes hepatitis B D006509
T8 1038-1041 DiseaseOrPhenotypicFeature denotes HCC DISEASE|D006528
T10 1080-1091 DiseaseOrPhenotypicFeature denotes hepatitis B D006509
T11 1203-1215 DiseaseOrPhenotypicFeature denotes inflammation D007249
T12 1563-1576 DiseaseOrPhenotypicFeature denotes liver failure D017093
T13 2029-2041 DiseaseOrPhenotypicFeature denotes inflammation D007249
T14 2299-2304 DiseaseOrPhenotypicFeature denotes tumor D009369
T15 2388-2393 DiseaseOrPhenotypicFeature denotes tumor D009369
T16 2394-2402 DiseaseOrPhenotypicFeature denotes thrombus D013927
T17 2427-2443 DiseaseOrPhenotypicFeature denotes resection margin D000072662
T18 2547-2555 DiseaseOrPhenotypicFeature denotes fibrosis D005355
T19 2581-2586 DiseaseOrPhenotypicFeature denotes tumor D009369
T20 2678-2683 DiseaseOrPhenotypicFeature denotes tumor D009369
T21 2684-2692 DiseaseOrPhenotypicFeature denotes thrombus D013927
T22 2696-2712 DiseaseOrPhenotypicFeature denotes resection margin D000072662
T23 2908-2911 DiseaseOrPhenotypicFeature denotes HCC DISEASE|D006528

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-164 Sentence denotes Posthepatectomy HBV reactivation in hepatitis B-related hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBV-DNA levels.
T2 165-175 Sentence denotes OBJECTIVE:
T3 176-451 Sentence denotes This study aimed to clarify the incidence of hepatitis B virus (HBV) reactivation and its significance on long-term survival after partial hepatectomy in patients with HBV-related hepatocellular carcinoma (HCC), who had preoperative low HBV-DNA level of less than 2000 IU/mL.
T4 452-582 Sentence denotes BACKGROUND: HBV reactivation is a frequent complication of systemic chemotherapy in hepatitis B surface antigen-positive patients.
T5 583-695 Sentence denotes Surgery and anesthesia result in a generalized state of immunosuppression in the immediate postoperative period.
T6 696-780 Sentence denotes Data on HBV reactivation and its significance after partial hepatectomy are unclear.
T7 781-802 Sentence denotes PATIENTS AND METHODS:
T8 803-888 Sentence denotes Consecutive patients from January 2006 to December 2007 were retrospectively studied.
T9 889-955 Sentence denotes RESULTS: HBV reactivation happened in 19.1% of patients in 1 year.
T10 956-1053 Sentence denotes There were 28 patients whose HBV reactivation was detected after the diagnosis of HCC recurrence.
T11 1054-1470 Sentence denotes On multivariate analysis, hepatitis B e antigen (HBeAg) positivity, preoperative HBV-DNA above the lower limit of quantification (≥200 IU/mL), Ishak inflammation score of greater than 3, preoperative transarterial chemoembolization (TACE), operation time of more than 180 minutes, blood transfusion, and without prophylactic antiviral therapy were significantly associated with an increased risk of HBV reactivation.
T12 1471-1542 Sentence denotes HBV reactivation negatively influenced postoperative hepatic functions.
T13 1543-1703 Sentence denotes The posthepatectomy liver failure rate in patients with HBV reactivation was significantly higher than in those without reactivation (11.8% vs 6.4%; P = 0.002).
T14 1704-1960 Sentence denotes The 3-year disease-free survival (DFS) rate and overall survival (OS) rates after resection in patients with HBV reactivation were significantly lower than those without reactivation (34.1% vs 46.0%; P = 0.009, and 51.6% vs 67.2%; P < 0.001, respectively).
T15 1961-2226 Sentence denotes HBeAg positivity, detectable preoperative HBV-DNA level, high Ishak inflammation score, preoperative TACE, long operation time, and blood transfusion were independent risk factors for HBV reactivation, whereas prophylactic antiviral therapy was a protective factor.
T16 2227-2499 Sentence denotes HBV reactivation, HBeAg positivity, HBV-DNA level of 200 IU/mL or more, tumor diameter greater than 5 cm, presence of satellite nodules, presence of portal vein tumor thrombus, blood transfusion, and resection margin less than 1.0 cm were independent risk factors for DFS.
T17 2500-2824 Sentence denotes A HBV-DNA level of 200 IU/mL or more, an Ishak fibrosis score of 4 or greater, a tumor diameter greater than 5 cm, the presence of satellite nodules, the presence of portal vein tumor thrombus, a resection margin less than 1.0 cm, no prophylactic antiviral therapy, and HBV reactivation were independent risk factors for OS.
T18 2825-2974 Sentence denotes CONCLUSIONS: HBV reactivation was common after partial hepatectomy for HBV-related HCC with a preoperative low HBV-DNA level of less than 2000 IU/mL.
T19 2975-3059 Sentence denotes Routine prophylactic antiviral treatment should be given before partial hepatectomy.
T1 0-164 Sentence denotes Posthepatectomy HBV reactivation in hepatitis B-related hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBV-DNA levels.
T2 165-175 Sentence denotes OBJECTIVE:
T3 176-451 Sentence denotes This study aimed to clarify the incidence of hepatitis B virus (HBV) reactivation and its significance on long-term survival after partial hepatectomy in patients with HBV-related hepatocellular carcinoma (HCC), who had preoperative low HBV-DNA level of less than 2000 IU/mL.
T4 452-582 Sentence denotes BACKGROUND: HBV reactivation is a frequent complication of systemic chemotherapy in hepatitis B surface antigen-positive patients.
T5 583-695 Sentence denotes Surgery and anesthesia result in a generalized state of immunosuppression in the immediate postoperative period.
T6 696-780 Sentence denotes Data on HBV reactivation and its significance after partial hepatectomy are unclear.
T7 781-802 Sentence denotes PATIENTS AND METHODS:
T8 803-888 Sentence denotes Consecutive patients from January 2006 to December 2007 were retrospectively studied.
T9 889-955 Sentence denotes RESULTS: HBV reactivation happened in 19.1% of patients in 1 year.
T10 956-1053 Sentence denotes There were 28 patients whose HBV reactivation was detected after the diagnosis of HCC recurrence.
T11 1054-1470 Sentence denotes On multivariate analysis, hepatitis B e antigen (HBeAg) positivity, preoperative HBV-DNA above the lower limit of quantification (≥200 IU/mL), Ishak inflammation score of greater than 3, preoperative transarterial chemoembolization (TACE), operation time of more than 180 minutes, blood transfusion, and without prophylactic antiviral therapy were significantly associated with an increased risk of HBV reactivation.
T12 1471-1542 Sentence denotes HBV reactivation negatively influenced postoperative hepatic functions.
T13 1543-1703 Sentence denotes The posthepatectomy liver failure rate in patients with HBV reactivation was significantly higher than in those without reactivation (11.8% vs 6.4%; P = 0.002).
T14 1704-1960 Sentence denotes The 3-year disease-free survival (DFS) rate and overall survival (OS) rates after resection in patients with HBV reactivation were significantly lower than those without reactivation (34.1% vs 46.0%; P = 0.009, and 51.6% vs 67.2%; P < 0.001, respectively).
T15 1961-2226 Sentence denotes HBeAg positivity, detectable preoperative HBV-DNA level, high Ishak inflammation score, preoperative TACE, long operation time, and blood transfusion were independent risk factors for HBV reactivation, whereas prophylactic antiviral therapy was a protective factor.
T16 2227-2499 Sentence denotes HBV reactivation, HBeAg positivity, HBV-DNA level of 200 IU/mL or more, tumor diameter greater than 5 cm, presence of satellite nodules, presence of portal vein tumor thrombus, blood transfusion, and resection margin less than 1.0 cm were independent risk factors for DFS.
T17 2500-2824 Sentence denotes A HBV-DNA level of 200 IU/mL or more, an Ishak fibrosis score of 4 or greater, a tumor diameter greater than 5 cm, the presence of satellite nodules, the presence of portal vein tumor thrombus, a resection margin less than 1.0 cm, no prophylactic antiviral therapy, and HBV reactivation were independent risk factors for OS.
T18 2825-2974 Sentence denotes CONCLUSIONS: HBV reactivation was common after partial hepatectomy for HBV-related HCC with a preoperative low HBV-DNA level of less than 2000 IU/mL.
T19 2975-3059 Sentence denotes Routine prophylactic antiviral treatment should be given before partial hepatectomy.

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 356-380 HP_0001402 denotes hepatocellular carcinoma

Allie

Id Subject Object Predicate Lexical cue
SS1_22868358_2_0 221-238 expanded denotes hepatitis B virus
SS2_22868358_2_0 240-243 abbr denotes HBV
SS1_22868358_2_1 356-380 expanded denotes hepatocellular carcinoma
SS2_22868358_2_1 382-385 abbr denotes HCC
SS1_22868358_12_0 1080-1101 expanded denotes hepatitis B e antigen
SS2_22868358_12_0 1103-1108 abbr denotes HBeAg
SS1_22868358_12_1 1254-1285 expanded denotes transarterial chemoembolization
SS2_22868358_12_1 1287-1291 abbr denotes TACE
SS1_22868358_15_0 1715-1736 expanded denotes disease-free survival
SS2_22868358_15_0 1738-1741 abbr denotes DFS
SS1_22868358_15_1 1752-1768 expanded denotes overall survival
SS2_22868358_15_1 1770-1772 abbr denotes OS
AE1_22868358_2_0 SS1_22868358_2_0 SS2_22868358_2_0 abbreviatedTo hepatitis B virus,HBV
AE1_22868358_2_1 SS1_22868358_2_1 SS2_22868358_2_1 abbreviatedTo hepatocellular carcinoma,HCC
AE1_22868358_12_0 SS1_22868358_12_0 SS2_22868358_12_0 abbreviatedTo hepatitis B e antigen,HBeAg
AE1_22868358_12_1 SS1_22868358_12_1 SS2_22868358_12_1 abbreviatedTo transarterial chemoembolization,TACE
AE1_22868358_15_0 SS1_22868358_15_0 SS2_22868358_15_0 abbreviatedTo disease-free survival,DFS
AE1_22868358_15_1 SS1_22868358_15_1 SS2_22868358_15_1 abbreviatedTo overall survival,OS